Daxor Corporation Announces An Update On Its Stock Buyback Program And Changes In Marketing

NEW YORK, NY--(Marketwired - August 13, 2015) -

The Board of Directors of Daxor Corporation has given management the authority to repurchase up to 250,000 shares of its common stock in 2015. From January 1, 2015 through August 12, 2015, the company has repurchased 126,167 shares of its common stock. The company can repurchase up to another 123,833 shares before the end of 2015. During the year ended December 31, 2014, the company repurchased 98,672 shares of its common stock.

As of August 12, 2015, 3,864,729 shares of the company's common stock was outstanding. Of this amount, 3,176,029 shares or 82.2% were held or controlled by insiders. 688,710 shares or 17.8% were owned by non-insiders.

The company is in the process of making major changes in its marketing and educational program. Blood volume derangements are at the core of major medical problems such as congestive heart failure, sepsis in intensive care unit patients, and renal dialysis patients in kidney failure. Blood volume measurement is severely underutilized. The company has recognized that in order to achieve its goal of making blood volume a standard of care incorporating its unique technology, it needs to obtain the services of individuals with extensive experience in medical marketing. The company has already retained the services of some individuals with expertise in this area and will have further announcements in the near future with respect to these changes.

The BVA-100 blood volume analyzer is in 72 hospitals in the U. S. such as NYU Medical Center, the Cleveland Clinic, the Mayo Clinic, Christiana Medical Center.

The Daxor website provides important additional information to help patients understand the benefit of blood volume measurement and which medical facilities in various states across the country are able to provide this life saving test.

To learn more about Daxor, please visit www.Daxor.com.